On the morning of February 9, 2026, a research team from the Affiliated Hospital of Qinghai University visited Shenzhen-Hong Kong Cell Valley to conduct special research and cooperation negotiations.The research team was led by President Fan Haining, and was attended by Vice President Ma Yanyan, Party Committee Member Su Juan, and experts from key disciplines such as stem cells and regenerative medicine, imaging, blood tumors, and rheumatism and immunity.

Visitors include: Fan Haining (Dean and Deputy Secretary of the Party Committee of the Affiliated Hospital of Qinghai University), Ma Yanyan (Vice President), Su Juan (Member of the Party Committee), Cui Sen (Academic Director of the Stem Cell and Regenerative Medicine Laboratory), Bao Haihua (Director of the Imaging Center), Geng Hui (Director of the Hematology Oncology Department), Liu Chuanchuan (Stem Cell and Regenerative Medicine Laboratory), Liu Huihui (Rheumatology and Immunology Department), etc.Shi Yuanyuan, Chairman of Cell Valley Group, and Wang Jianxun, Chief Scientist, etc. warmly received him.

The research team visited the one-stop platform construction of Shenzhen-Hong Kong Cell Valley in the field of cell and gene therapy.As one of the few domestic platform companies with clinical-grade cell preparation capabilities, mature quality systems and practical experience in cross-border delivery, Cell Valley has formed a full-chain capability of "R&D-preparation-quality control-clinical transformation-international delivery" and has significant first-mover advantages in the fields of immune cells, stem cells and related derivative technologies.Relying on the institutional innovation environment of coordinated development between Shenzhen and Hong Kong, Shenzhen-Hong Kong Cell Valley has outstanding platform value in terms of compliance path design, clinical research implementation efficiency, and international docking.

At the symposium, President Fan Haining introduced that as an important regional medical and scientific research center in the Qinghai-Tibet Plateau, the Affiliated Hospital of Qinghai University has long been engaged in plateau medical research, and has accumulated distinctive features and rich clinical resources in aspects such as tumorigenesis mechanisms, autoimmune diseases, blood system diseases and multi-system adaptive changes in plateau hypoxic environments.Relying on the unique physiological and immunological characteristics of the plateau population, the hospital has formed regionally representative research directions, providing irreplaceable real-world scenarios for the verification and transformation of new treatment technologies.In addition, the Affiliated Hospital of Qinghai University has recently officially established a cell therapy center. Professor Cui Sen, the former party secretary of the hospital and an expert in hematology, serves as the director. It conducts a systematic layout around the clinical research, technology transformation and standardized application of cell therapy, focusing on exploring the clinical value of cell therapy in plateau-specific diseases, tumors and immune-related diseases.This move marks a key step for the hospital in the layout of cutting-edge medical technology and interdisciplinary integration, and also provides an important platform support for the in-depth integration of plateau medicine and cell therapy.

Chairman Shi Yuanyuan of Cell Valley said that the special physiological environment and disease spectrum faced by plateau medicine provide extremely valuable research scenarios for the verification and innovative application of cell therapy technology.In the future, both parties can rely on Cell Valley's advantages in platforming, standardization, and large-scale implementation to complement the clinical and scientific research accumulation of Qinghai University Affiliated Hospital in the field of plateau medicine, and carry out substantive cooperation in joint scientific research, multi-center IIT research, design of cell therapy programs for characteristic diseases, exploration of clinical transformation paths, and talent cultivation.

This survey laid a solid foundation for both parties to establish a long-term and stable industry-university-research-medical cooperation mechanism. In the next step, the two parties will focus on the integration of plateau medicine's characteristic diseases and cell therapy technology, accelerate the implementation of specific cooperation projects, and promote the innovative development of cell and regenerative medicine in my country's diverse populations and complex environments.

微信公众号

市场部：赖女士